PMG
IONS icon

ProVise Management Group’s Ionis Pharmaceuticals IONS Stock Holding History

ProVise Management Group’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,111
Closed -$244K – 391
2021
Q2 		$244K Buy
6,111
+307
+5% +$12K 0.02% 333
2021
Q1 		$261K Buy
+5,804
New +$324K 0.03% 301

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ProVise Management Group's IONS Position: Q3 2021 in Review

ProVise Management Group sold out of Ionis Pharmaceuticals (IONS) in Q3 2021, closing a stake of 6,111 shares — an estimated $244K sold.

ProVise Management Group first reported a position in IONS in Q1 2021 and held it in 2 quarters. The position peaked at $261K in Q1 2021. 324 funds tracked by Wall St. Rank hold IONS as of Q3 2021.

  • ProVise Management Group reported no remaining Ionis Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • ProVise Management Group sold 6,111 Ionis Pharmaceuticals shares in Q3 2021, an estimated $244K.
  • ProVise Management Group first reported a position in Ionis Pharmaceuticals in Q1 2021 and held it in 2 quarters.
  • ProVise Management Group's Ionis Pharmaceuticals position peaked at $261K in Q1 2021.
  • 324 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2021.

Based on ProVise Management Group's 13F filing for Q3 2021, filed 20 Oct 2021.